28.5.2021 10:27:30 CEST | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 13-2021 - 28 May 2021

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces Gemelli University Hospital in Rome as its first clinical routine customer in Italy.

Gemelli University Hospital is one of the largest hospitals in Italy with 1,575 beds and an uptake population of approximately 1.5 million people. suPARnostic® TurbiLatex has been implemented in the central laboratory on the Siemens ADVIA XPT clinical chemistry analyser.

Prof. Andrea Urbani and dr.ssa Silvia Baroni, Corelab Clinical Biochemistry, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome said: ”We are excited about being the first hospital in Italy to implement the prognostic biomarker suPAR in clinical routine for risk stratification of COVID-19 patients.”

Gemelli University Hospital is one of the study sites from the previously announced SAVE-MORE clinical trial. Initially, the hospital will use suPARnostic® for risk stratification of COVID-19 patients.

ViroGates serves its Italian customers through the distributor B.S.N. Srl Biological Sales Network.

Partner Giacinto Guercilena, B.S.N. Srl said: “Being a long-term Partner of ViroGates, it is a pleasure to note that a major Italian university hospital has begun using suPAR in the emergency department. In addition to earlier treatment of the ill patients, this may also lead to cost savings, as unnecessary admissions can be avoided.”

Jakob Knudsen, Chief Executive Officer of ViroGates, said: ”We are excited to announce our first Italian routine customer and honoured to serve the renowned Gemelli University Hospital. In addition, we are happy to learn that Gemelli wants to continue using suPARnostic® to triage COVID-19 patients following the hospital’s participation in the SAVE-MORE trial. We are working closely together with our distributor, B.S.N., who is spearheading our efforts in Italy to improve outcomes for patients all over the country.”

The announcement can be found at https://www.virogates.com/investor/announcements 

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 700 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

• 20210528-ViroGates company announcement 13.pdf